Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) Price Target at $91.20

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has received a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $91.20.

Several research analysts have recently issued reports on HALO shares. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, July 31st. TD Cowen raised their price target on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Wells Fargo & Company boosted their price objective on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Finally, Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th.

Insider Activity

In related news, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director directly owned 14,462 shares of the company’s stock, valued at $1,084,650. This trade represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $67.58, for a total value of $1,351,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at $51,886,572.40. The trade was a 2.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 44,103 shares of company stock valued at $3,142,896 over the last ninety days. 2.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Halozyme Therapeutics

A number of large investors have recently made changes to their positions in the stock. Mizuho Markets Americas LLC boosted its stake in shares of Halozyme Therapeutics by 270.8% in the fourth quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock worth $85,382,000 after acquiring an additional 926,526 shares during the period. Paragon Capital Management Inc. purchased a new stake in shares of Halozyme Therapeutics during the fourth quarter worth about $1,273,000. Hussman Strategic Advisors Inc. raised its stake in Halozyme Therapeutics by 66.7% during the 4th quarter. Hussman Strategic Advisors Inc. now owns 52,500 shares of the biopharmaceutical company’s stock valued at $3,533,000 after purchasing an additional 21,000 shares during the period. Northwestern Mutual Wealth Management Co. raised its stake in Halozyme Therapeutics by 19,326.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 85,476 shares of the biopharmaceutical company’s stock valued at $5,753,000 after purchasing an additional 85,036 shares during the period. Finally, Assetmark Inc. lifted its holdings in Halozyme Therapeutics by 11.9% in the 4th quarter. Assetmark Inc. now owns 137,415 shares of the biopharmaceutical company’s stock worth $9,248,000 after purchasing an additional 14,568 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $100.67 on Tuesday. Halozyme Therapeutics has a 1-year low of $61.22 and a 1-year high of $104.78. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The business has a fifty day moving average price of $79.11 and a 200-day moving average price of $72.36. The company has a market capitalization of $11.43 billion, a PE ratio of 30.05, a PEG ratio of 0.41 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.Halozyme Therapeutics’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities analysts expect that Halozyme Therapeutics will post 7.77 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.